In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Anthony H. Goldstone(Royal London Hospital), Jacob M. Rowe(Technion – Israel Institute of Technology), Letizia Foroni(Centre for Inflammation Research), Selina M. Luger(University of Pennsylvania), Andrew McMillan(Nottingham University Hospitals NHS Trust), Jill Durrant(MRC Clinical Trials Unit at UCL), Hillard M. Lazarus(University Hospitals of Cleveland), Georgina Buck(MRC Clinical Trials Unit at UCL), Elisabeth Paietta(Montefiore Medical Center), Adele K. Fielding(New York Blood Center), Mark R. Litzow(Mayo Clinic in Arizona), Peter H. Wiernik(Albert Einstein College of Medicine), Niculae Ciobanu(New York Stem Cell Foundation), Susan Richards(MRC Clinical Trials Unit at UCL), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Raj Chopra(National Health Service), Alan K. Burnett(Cardiff University)
Cited by 782
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k